通过用福尔马林灭活呼吸道合胞病毒进行被动免疫产生的母源抗体可提供保护，且不会引发疫苗增强性疾病。
Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease.
作者信息
Kwon Young-Man, Hwang Hye Suk, Lee Jong Seok, Ko Eun-Ju, Yoo Si-Eun, Kim Min-Chul, Lee Yu-Na, Kim Ki-Hye, Song Jae-Min, Lee Sujin, Moore Martin L, Kang Sang-Moo
机构信息
Center for Inflammation, Immunity & Infection, and Department of Biology, Georgia State University, Atlanta, GA 30303, USA.
Animal and Plant Quarantine Agency, Anyang, Gyeonggi-do, South Korea.
出版信息
Antiviral Res. 2014 Apr;104:1-6. doi: 10.1016/j.antiviral.2014.01.008. Epub 2014 Jan 23.
Abstract
Maternal immunization of mice with formalin inactivated respiratory syncytial virus (FI-RSV) resulted in the passive transfer of RSV antibodies but not cellular components to the offspring. The offspring born to FI-RSV immunized mothers showed serum RSV neutralizing activity, effectively controlled lung viral loads without vaccine-enhanced disease, did not induce pulmonary eosinophilia, and cytokine producing cells after live RSV infection. Therefore, this study provides evidence that maternal immunization provides an in vivo model in investigating the roles of antibodies independent of cellular components.
摘要
用福尔马林灭活呼吸道合胞病毒（FI-RSV）对小鼠进行母体免疫，可导致RSV抗体而非细胞成分被动转移给后代。FI-RSV免疫的母亲所生的后代表现出血清RSV中和活性，有效控制肺部病毒载量且无疫苗增强疾病，不诱导肺部嗜酸性粒细胞增多，也不诱导活RSV感染后的细胞因子产生细胞。因此，本研究提供了证据表明母体免疫为研究抗体独立于细胞成分的作用提供了一种体内模型。
相似文献
1
Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease.
Antiviral Res. 2014 Apr;104:1-6. doi: 10.1016/j.antiviral.2014.01.008. Epub 2014 Jan 23.
2
Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice.
Vaccine. 2000 Nov 22;19(7-8):982-91. doi: 10.1016/s0264-410x(00)00213-9.
3
A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease.
PLoS One. 2011;6(7):e21823. doi: 10.1371/journal.pone.0021823. Epub 2011 Jul 15.
4
Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease.
Antiviral Res. 2015 Mar;115:1-8. doi: 10.1016/j.antiviral.2014.12.009. Epub 2014 Dec 13.
5
Maternal transfer of RSV immunity in cotton rats vaccinated during pregnancy.
Vaccine. 2015 Oct 5;33(41):5371-5379. doi: 10.1016/j.vaccine.2015.08.071. Epub 2015 Aug 31.
6
Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
Clin Vaccine Immunol. 2016 Jun 6;23(6):451-9. doi: 10.1128/CVI.00720-15. Print 2016 Jun.
7
Enhancement of Respiratory Syncytial Virus Infection by Maternal Antibodies Does Not Explain Disease Severity in Infants.
J Virol. 2017 Oct 13;91(21). doi: 10.1128/JVI.00851-17. Print 2017 Nov 1.
8
Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice.
PLoS One. 2013 Dec 23;8(12):e83075. doi: 10.1371/journal.pone.0083075. eCollection 2013.
9
Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis.
Antiviral Res. 2014 Oct;110:115-23. doi: 10.1016/j.antiviral.2014.07.016. Epub 2014 Aug 7.
10
Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
J Virol. 2015 Nov;89(22):11692-705. doi: 10.1128/JVI.02018-15. Epub 2015 Sep 9.
引用本文的文献
1
Lung ILC2s are activated in BALB/c mice born to immunized mothers despite complete protection against respiratory syncytial virus.
Front Immunol. 2024 May 17;15:1374818. doi: 10.3389/fimmu.2024.1374818. eCollection 2024.
2
Exacerbated lung inflammation following secondary RSV exposure is CD4+ T cell-dependent and is not mitigated in infant BALB/c mice born to PreF-vaccinated dams.
Front Immunol. 2023 Aug 14;14:1206026. doi: 10.3389/fimmu.2023.1206026. eCollection 2023.
3
Evolution of protection after maternal immunization for respiratory syncytial virus in cotton rats.
PLoS Pathog. 2021 Dec 23;17(12):e1009856. doi: 10.1371/journal.ppat.1009856. eCollection 2021 Dec.
4
Strategies for active and passive pediatric RSV immunization.
Ther Adv Vaccines Immunother. 2021 Feb 10;9:2515135520981516. doi: 10.1177/2515135520981516. eCollection 2021.
5
Recombinant Live Attenuated Influenza Virus Expressing Conserved G-Protein Domain in a Chimeric Hemagglutinin Molecule Induces G-Specific Antibodies and Confers Protection against Respiratory Syncytial Virus.
Vaccines (Basel). 2020 Dec 1;8(4):716. doi: 10.3390/vaccines8040716.
6
Maternal immunization with adjuvanted RSV prefusion F protein effectively protects offspring from RSV challenge and alters innate and T cell immunity.
Vaccine. 2020 Nov 25;38(50):7885-7891. doi: 10.1016/j.vaccine.2020.10.065. Epub 2020 Oct 29.
7
Antigenicity and immunogenicity of unique prefusion-mimic F proteins presented on enveloped virus-like particles.
Vaccine. 2019 Oct 16;37(44):6656-6664. doi: 10.1016/j.vaccine.2019.09.041. Epub 2019 Sep 18.
8
Pregnancy and infection: using disease pathogenesis to inform vaccine strategy.
NPJ Vaccines. 2018 Feb 1;3:6. doi: 10.1038/s41541-017-0042-4. eCollection 2018.
9
Preclinical assessment of safety of maternal vaccination against respiratory syncytial virus (RSV) in cotton rats.
Vaccine. 2017 Jul 13;35(32):3951-3958. doi: 10.1016/j.vaccine.2017.06.009. Epub 2017 Jun 16.
10
Roles of Aluminum Hydroxide and Monophosphoryl Lipid A Adjuvants in Overcoming CD4+ T Cell Deficiency To Induce Isotype-Switched IgG Antibody Responses and Protection by T-Dependent Influenza Vaccine.
J Immunol. 2017 Jan 1;198(1):279-291. doi: 10.4049/jimmunol.1600173. Epub 2016 Nov 23.
本文引用的文献
1
Palivizumab use during respiratory syncytial virus outbreak in the neonatal intensive care unit.
J Hosp Infect. 2012 Aug;81(4):292-3. doi: 10.1016/j.jhin.2012.05.011. Epub 2012 Jun 20.
2
Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice.
PLoS One. 2012;7(5):e36812. doi: 10.1371/journal.pone.0036812. Epub 2012 May 9.
3
Palivizumab and emerging therapies for respiratory syncytial virus.
Expert Opin Biol Ther. 2012 May;12(5):547-8; author reply 549. doi: 10.1517/14712598.2012.665048. Epub 2012 Feb 21.
4
Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
Pediatr Infect Dis J. 2012 Jan;31(1):e1-8. doi: 10.1097/INF.0b013e318235455b.
5
Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice.
J Infect Dis. 2011 Oct 1;204(7):987-95. doi: 10.1093/infdis/jir474.
6
Multiple CD4+ T cell subsets produce immunomodulatory IL-10 during respiratory syncytial virus infection.
J Immunol. 2011 Sep 15;187(6):3145-54. doi: 10.4049/jimmunol.1100764. Epub 2011 Aug 15.
7
Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.
Immunol Rev. 2011 Jan;239(1):149-66. doi: 10.1111/j.1600-065X.2010.00972.x.
8
Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles.
Virology. 2010 Sep 15;405(1):165-75. doi: 10.1016/j.virol.2010.05.034. Epub 2010 Jun 26.
9
The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya.
PLoS One. 2009 Dec 2;4(12):e8088. doi: 10.1371/journal.pone.0008088.
10
Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.
J Virol. 2010 Jan;84(2):1110-23. doi: 10.1128/JVI.01709-09. Epub 2009 Nov 4.
Zotero 插件